It's been more than a day since you last mentioned the missed FF deadline which was apparently something that Cynata came up with.
Let me help you.
You said (and will soon say again):
"Firstly, we both agree that Cynata (RM) stated that with FF, Cynata could commercialise by 2024 (not 2022 - details are important, DH).
One of my points is that FF said no such thing. As I have previously REMINDED you (above), FF told Cynata nothing much at all. You going back to 2016 and trying to pin statements made in the afterglow of the original deal does indeed make you look silly (amongst other things), but this makes you look even sillier (refer, "REMINDED you" previously) [...]."
FF told Cynata nothing much at all, you posted a link of RMD saying that. Which is true, never been a question.
I then posted a FF presentation to all their shareholders:
I even got you the historic link to the FF website to the presentation:
https://web.archive.org/web/20180516065056/https://www.fujifilmholdings.com/en/pdf/investors/other/ff_presentation_20161208_001.pdf
https://web.archive.org/web/20180516065056/https://www.fujifilmholdings.com/en/pdf/investors/other/ff_presentation_20161208_001.pdfPreviously I have quoted a January 2017 interview with Junji Okada, Director, Corporate VP & GM of Corporate Planning Headquarters and Pharmaceuticals Products Divs., FujiFilm Holdings Corporation, published in "Weekly Diamond"'s January Edition with the title "FujiFilm pushing into regenerative medical business" (sorry, my links are dead but against a few that article is still available via their website):
"Get a challenge right to become a main player
We have elemental technologies cultivated with film. In the field of regenerative medicine, there are no companies in the world who have established a firm position yet. As a pharmaceutical manufacturer, we are "chase after". Even if imitating after the major and keeping up, profitability is not good and efficiency is bad. If you go out early in areas where no one is doing, you will gain the challenge of becoming a main player.
We are steadily striking the foundation necessary for regenerative medicine . Mostly it is acquisition. We are holding down all three major elements (cell, medium, scaffold) in regenerative medicine. I think that business can be deployed comprehensively just by regenerative medicine. Then you get inquiries from various places and information comes in, so you can further lead the industry.
- I am aiming for the first domestic company trial in transplant medical treatment using iPS cells in 19 years.
It is the impression that we are finally getting into the stage of business. Since I do it, I want to honor the first domestic. There is also a pride that it is a top runner in the field of regenerative medicine."
Still in October 2018, an article with the title iPS-derived mesenchymal stem cells, next year at the prospect Japan-US clinical trial Fujifilm, etc. was published on nikkan.co.jp stating the following:
"The MSC used in Phase 2 trials is supplied from the United States, but in the future, it is also considering production at Japan Tissue Engineering (J-TEC) of the Fujifilm Group."
https://www.nikkan.co.jp/articles/view/00492098Ken-ichiro Hata, Deputy Director BioScience & Technology Development Center, Fujifilm Corporation Japan Tissue Engineering Co., Ltd. (J - TEC), Representative Director and President, for example in December 2018 said the following:
"There are many walls that must be overcome in order to make organs from iPS cells, but research and development of cell therapy using iPS cells is progressing steadily. CDI also supplies iPS cells to the Australian regenerative medical venture in the Fujifilm Group and contributes to the world's first iPS cell clinical trial in the UK. This is to inject a mesenchymal stem cell (* 3) made from iPS cells and treat it for patients with complications that occur after leukemia bone marrow transplantation. And Fujifilm will do the same clinical trial in Japan, as a company in 2019 for the first time. If approval from the country is obtained, I would like to sell it to medical institutions as a formulation."
https://brand.fujifilm.co.jp/healthcare/interview/interview3.html(must use webarchive to view, as the website has since changed)
Also in December 2018, FujiFilm was quoted saying:
Fujifilm announced on Wednesday that it will establish a facility for production of artificial pluripotent stem cells (iPS cells) for treatment in Wisconsin State, USA. Investment amount is about 2.5 billion yen. It is intended to accelerate the development of regenerative medicine products using iPS cells and to operate it in FY 2019.
Fujifilm plans to apply for a clinical trial (clinical trial) for obtaining approval of transplantation medicine by iPS cells from the country in Japan during FY 2018. We plan to conduct clinical trials in the United States.
A US subsidiary is set up as a production facility, and introduction of cultivation equipment and so on corresponding to the quality control standards of US authorities. Rapidly develop regenerative medical products in the fields of Parkinson's disease, heart disease, cancer by iPS cells produced. We also assume production contracts from other companies.
https://www.sankei.com/life/news/181220/lif1812200031-n1.htmlYour point was FF never said such thing as the above. Never. NEVER. All made up. It was Cynata. Cynata. CYNATA. Ross. Cynata. Sector dressed as Ross? Ross dressed as Sector?
And all that because of your ability to sense Cynata BS and pointing out that the above timeline announced by Cy... FujiFilm was incorrect and didn't happen and FF handed back the indication, therefore not running the trial as planned.
The above are just in your words "facts", yep "". The "" used to double down (man, I hope you don't play poker, going "all in" when you already know that you only have garbage on hand) on your incorrect statement (I'll add it to the list).
Now a question:
2010 plus 3 years is 2024 (if all goes well, third time lucky)?
“We believe bone marrow transplantation is potentially the fastest revenue generator moving into the phase three trial phase. We expect to start this early in the new year with a focus to getting it to market within three years," he said.
https://www.copyright link/companies/healthcare-and-fitness/mesoblast-poised-to-charge-ahead-among-biotechs-20101130-j5756Let me guess, Cynata made that statement, too. Obviously. And the person in the pics is really Ross, wearing a wig and a morph suit. Gotcha.
There is always bigger mailbox... fish to fry.
Convo is over, yeah, nah. Still so much to cover, but so little time.
Which one is smaller?
(20min delay)